Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 07, 2022 07:00 ET | Source: Amryt Pharma plc

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022

Amryt Presents New Analyses from the EASE Phase 3 Trial in Epidermolysis Bullosa at SPD 2022 - Key highlights include efficacy of Oleogel-S10 (birch triterpenes) on accelerated wound healing, data on...
July 01, 2022 07:00 ET | Source: Amryt Pharma plc

Results of Annual General Meeting

DUBLIN, Ireland, and Boston MA, July 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare...
June 27, 2022 07:00 ET | Source: Amryt Pharma plc

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer

Amryt Announces Appointment of Dr Tracy Cunningham as Chief Medical Officer DUBLIN, Ireland, and Boston MA, June 27, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company...
June 24, 2022 07:00 ET | Source: Amryt Pharma plc

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA

Amryt to Pursue Formal Dispute Resolution for Oleogel-S10 (Filsuvez®) NDA Filsuvez® recently approved by the European Commission for the treatment of EB DUBLIN, Ireland, and Boston MA, June 24,...
June 23, 2022 07:00 ET | Source: Amryt Pharma plc

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB

European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB Filsuvez® will be the first and only approved treatment for EB Patients DUBLIN, Ireland, and Boston MA,...
June 13, 2022 08:00 ET | Source: Amryt Pharma plc

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022

Amryt Presents Data for Mycapssa® (oral octreotide) from OPTIMAL and MPOWERED Phase 3 Trials at ENDO 2022 Data from the MPOWERED OLE and first presentation of open-label extension (OLE) data from 2nd...
June 08, 2022 07:00 ET | Source: Amryt Pharma plc

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022

Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022 DUBLIN, Ireland, and Boston MA, June 8, 2022 Amryt (Nasdaq: AMYT), a...
June 01, 2022 07:00 ET | Source: Amryt Pharma plc

Posting of Annual Report and Notice of AGM

Posting of Annual Report and Notice of AGM DUBLIN, Ireland, and Boston MA, June 1, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing...
May 17, 2022 07:00 ET | Source: Amryt Pharma plc

Amryt Announces Details of EMA Contingent Value Rights Payment

Amryt Announces Details of EMA Contingent Value Rights Payment DUBLIN, Ireland, and Boston MA, May 17, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to...
May 11, 2022 07:00 ET | Source: Amryt Pharma plc

Amryt Announces New Patent for Mycapssa®

Amryt Announces New Patent for Mycapssa® DUBLIN, Ireland, and Boston MA, May 11, 2022 Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...